| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 116, 499-502, Copyright © 1985 by Endocrine Society
ARTICLES |
AJ Baertschi and M Friedli
Suspensions of rat anterior pituitary cells were exposed to corticotropin-releasing factor (CRF) (5 nM) and various neurohormones (0.002-1000 nM). CRF-induced secretion of ACTH was doubled by 0.1 nM arginine vasopressin (AVP), 0.2 nM arginine vasotocin, 1 nM oxytocin, 10 nM angiotensin II, and 100 nM noradrenalin; vasoactive intestinal peptide had no effect at 0.2-200 nM. CRF potentiation by AVP was also observed at lower concentrations of CRF. Since AVP appeared to be the most potent modulator of CRF-induced ACTH secretion, potentiation was further tested with specific antidiuretic and oxytocic agonists. Potentiation was clearly related to pressor biological activity, less so to antidiuretic, and hardly at all to oxytocic activities. However, even at 200 nM, the antipressor antagonists dPTyr(Me)AVP and d(CH2)5Tyr(Me)AVP had no effect on potentiation by AVP. The lack of antagonism was partly due to the agonistic effects of the antagonists on the pituitary gland, an effect not observed within vascular tissue. The results thus suggest that anterior pituitary vasopressin receptors resemble, but are not identical to, V1 (pressor and hepatic), do not resemble the V2 (renal), and might be classified as V3 (pituitary) receptors.
This article has been cited by other articles:
![]() |
M. V. Mikhailova, P. R. Mayeux, A. Jurkevich, W. J. Kuenzel, F. Madison, A. Periasamy, Y. Chen, and L. E. Cornett Heterooligomerization between Vasotocin and Corticotropin-Releasing Hormone (CRH) Receptors Augments CRH-Stimulated 3',5'-Cyclic Adenosine Monophosphate Production Mol. Endocrinol., September 1, 2007; 21(9): 2178 - 2188. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Orcel, V. A. Tobin, G. Alonso, and A. Rabie Immunocytochemical Localization of Vasopressin V1a Receptors in the Rat Pituitary Gonadotropes Endocrinology, November 1, 2002; 143(11): 4385 - 4388. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Laszlo, C. Varga, I. Pavo, J. Gardi, M. Vecsernyes, M. Galfi, E. Morschl, F. Laszlo, and G. B. Makara Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2001; 280(2): R458 - R465. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moro, P. Putignano, M. Losa, C. Invitti, C. Maraschini, and F. Cavagnini The Desmopressin Test in the Differential Diagnosis between Cushing's Disease and Pseudo-Cushing States J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3569 - 3574. [Abstract] [Full Text] |
||||
![]() |
D. Engler, E. Redei, and I. Kola The Corticotropin-Release Inhibitory Factor Hypothesis: A Review of the Evidence for the Existence of Inhibitory as Well as Stimulatory Hypophysiotropic Regulation of Adrenocorticotropin Secretion and Biosynthesis Endocr. Rev., August 1, 1999; 20(4): 460 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. M. Dahia and A. B. Grossman The Molecular Pathogenesis of Corticotroph Tumors Endocr. Rev., April 1, 1999; 20(2): 136 - 155. [Abstract] [Full Text] |
||||
![]() |
M. Thibonnier, J. A. Preston, N. Dulin, P. L. Wilkins, L. N. Berti-Mattera, and R. Mattera The Human V3 Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways Endocrinology, October 1, 1997; 138(10): 4109 - 4122. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abel, N. Wittau, T. Wieland, G. Schultz, and F. Kalkbrenner Cell Cycle-dependent Coupling of the Vasopressin V1a Receptor to Different G Proteins J. Biol. Chem., October 13, 2000; 275(42): 32543 - 32551. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |